VEYVE® (cyclosporine opthalmic solution) 0.1% is shown to be well-tolerated.
Over 3 clinical studies, 99.8% of patients experienced no or mild site instillation irritation. In an open-label extension 52-week study, only 1 patient discontinued treatment due to
an ocular adverse reaction, which was mild burning and stinging.
In clinical trials with 738 subjects receiving at least 1 dose of VEVYE, the most common side effects include eye irritation (8%) and temporary blurred vision (3%).
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
To avoid the potential for eye injury and/or contamination, do not touch the bottle tip to the eye or other surfaces.
VEVYE should not be administered while wearing contact lenses. Remove contacts prior to using VEVYE. After applying wait 15 minutes before reinserting contact lenses.
The most common side effects include eye irritation (8%) and temporary blurred vision (3%).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For additional information about VEVYE, please see the Full Prescribing Information.